

OF THE WEEK

Venus tectonics, Pluto's surface	228
ACS Centennial celebration	230
Plant immunity elicitor	230
Bacteria-mammalian gene combo	231
Particle menagerie grows	231
Community mental health criticized	232
Diabetic blindness treatment	232

RESEARCH NOTES

Behavior	233
Chemistry	233
Space Sciences	234

ARTICLES

French solar furnace	235
Cinderella cash crops	237

DEPARTMENTS

Letters	227
---------	-----

COVER: High in the French Pyrenees, the world's largest solar furnace provides a pure radiant energy for a variety of experiments that would be difficult or impossible in ordinary electrical units. Eight stories tall, with an energy flux of 1000 kilowatts on a target, the giant parabola may be a prototype of similar, commercial devices. See page 235. (Photo: C. N. R. S. Research No. 2: Courtesy Saint-Gobain-J.P. Bonal)

Publisher	E. G. Sherburne Jr.
Editor	Kendrick Frazier
Senior Editor and Physical Sciences	Dietrick E. Thomsen
Senior Editor and Behavioral Sciences	Robert J. Trotter
Biomedical Sciences	Joan Arehart-Treichel
Biology/Chemistry	Janet L. Hopson
Science and Society	John H. Douglas
Space Sciences	Jonathan Eberhart
Contributing Editor/ Mathematics	Lynn Arthur Steen
Copy Editor	Michelle Galler Riegel
Art Director	Dale Appleman
Assistant to the Editor	Susan Strasburger
Books	Margit Friedrich
Advertising	Scherago Associates, Inc. 11 W. 42nd St. New York, N.Y. 10036 Fred W. Dieffenbach Sales Director

Copyright © 1976 by Science Service, Inc., 1719 N St., N.W., Washington, D.C. 20036. Reproduction of any portion of SCIENCE NEWS is prohibited.

Editorial and Business Offices
1719 N Street, N.W.
Washington, D.C. 20036

Subscription Department
231 West Center Street
Marion, Ohio 43302

Subscription rate: 1 yr., \$10; 2 yrs., \$18; 3 yrs., \$25. (Add \$2 a year for Canada and Mexico, \$3 for all other countries.) Change of address: Four to six weeks' notice is required. Please state exactly how magazine is to be addressed. Include zip code.

Printed in U.S.A. Second class postage paid at Washington, D.C. Title registered as trademark U.S. and Canadian Patent Offices.

Published every Saturday by SCIENCE SERVICE, Inc., 1719 N St., N.W., Washington, D.C. 20036. (202-785-2255). Cable SCIENSERV. Telex 64227.

APRIL 10, 1976

LETTERS

Inventors and companies

Mr. Iler's reaction to your article on corporate scientists (SN: 3/20/76, p. 179) is very disturbing to me. I'm a former engineer who has done important work for two different major corporations during my career, and it is my observation that the failure of the employers to pay royalties to its engineer (or other) inventors does more harm to the corporations than to the engineers. I have been granted almost 50 U.S. and foreign patents; my inventions have made literally millions for the companies. Until I left and became an independent consulting engineer I received "peanuts" from my employers.

When an engineer accepts employment he makes no guarantee that he will invent. Many excellent and successful engineers do not invent. Those who do make inventions contribute something over and above what they were employed to do, and they should be rewarded accordingly.

I have witnessed what happens to the company under the present system, many times over. The best and most prolific inventors invariably leave for better jobs, taking with them technical wealth not otherwise available to the company's competitors. Perhaps the most valuable part of this technical transfer never appears in the patents themselves and would never be lost to the employer if he adequately rewarded his own inventors.

William B. Elmer
Consulting Engineer
Andover, Mass.

Antiviral compound

As a speaker at the conference on antiviral drugs (SN: 3/20/76, p. 186), I am pleased to see the extensive coverage your magazine devoted to the subject.

Your reporting was more perceptive than that presented in a number of other publications. I believe, however, that you and the other news sources missed a very important and exciting point. At the present time only ara-A (Vira-A) and to a lesser extent ribavirin (Virazole) have shown promise in widespread clinical trials. Both drugs have antiviral activity at dose levels sufficiently below toxic levels to permit their systemic use. We believe—as you reported—this may be related to the drugs' ability to preferentially inhibit virus-associated functions while partially sparing cellular functions.

The point you missed is that there are compounds in earlier stages of biochemical and pharmacological development which inhibit viral functions while sparing cellular

functions absolutely. A compound developed by Dr. W. H. Prusoff of the Yale University best exemplifies this principle. The drug is referred to as AIU and can be phosphorylated (activated) only in cells infected with herpes simplex virus type I. The virus actually specifies the enzyme which is responsible for its own destruction.

As uninfected cells do not contain this form of the enzyme, such compounds should be highly specific and free of the toxicities usually associated with drugs that inhibit nucleic acid synthesis. The report of the accomplishment of such high specificity was the highlight of the conference for me. I believe this type of specificity is what we must aim for in developing antiviral drugs of the future.

J. C. Drach, Ph.D.
Associate Professor
The University of Michigan
School of Dentistry
Ann Arbor, Mich.

Federal energy centers

Your report on the McCormack subcommittee (of the Joint Committee on Atomic Energy) evaluation of the national Liquid Metal Fast Breeder Reactor Program (SN: 2/21/76, p. 117) neglected to mention an important point made by the Nuclear Regulatory Commission on federal "energy centers."

The NRC study referred to in the news story stated that it might be practical to design and build energy centers (with up to 20 nuclear power plants at each site), but it added that "it does not indicate any great or unequivocal advantage or compelling need for such centers." This conclusion was partially based on the fact that energy costs in transmitting electricity from the centers would offset the value of building them.

It is ironic that this news story failed to indicate the potential disadvantages of large nuclear power centers in the same issue of SCIENCE NEWS which carries a full page of letters critiquing your reporting of the national nuclear debate. It is no surprise that Mr. McCormack is in favor of breeder reactors, but it is surprising that your news coverage is not particularly objective.

Wilson Clark
Environmental Policy Institute
Washington, D.C.

("Objective reporting" has two aspects: In a brief news story, to accurately present the facts at hand; in a longer in-depth analysis, to fairly present both sides. As noted, this was strictly a news item about the breeder reactor report, with energy centers mentioned peripherally. We reported it "straight" and will continue to present and analyze both sides of these issues in signed, research roundups.—Ed.)

SCIENCE SERVICE

Institution for the Popularization of Science founded 1921; a nonprofit corporation

Board of Trustees—Nominated by the AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE: **Deborah P. Wolfe**, Queens College of City University of New York; **Bowen C. Dees**, The Franklin Institute; **Athelstan Spilhaus**, National Oceanic and Atmospheric Administration. Nominated by the NATIONAL ACADEMY OF SCIENCES: **Gerald F. Tape**, Associated Universities; **Allen V. Astin**, Bethesda, Md.; **Glenn T. Seaborg** (President), University of California, Berkeley. Nominated by the NATIONAL RESEARCH COUNCIL: **Gerald Holton**, Harvard University; **Joseph W. Berg Jr.**, National Research Council; **Aaron Rosenthal**, National Academy of Sciences. Nominated by the JOURNALISTIC PROFESSION: **Edward Bilss Jr.**, American University; **Julius Duschka**, Washington Journalism Center; **O. W. Riegel** (Secretary), Washington and Lee University. Nominated by E. W. Scripps Trust: **Milton Harris** (Treasurer), Washington, D.C.; **Edward W. Scripps II** (Vice President and Chairman of the Executive Committee), Edward W. Scripps Trust; **John Troan**, Pittsburgh Press.

Director: E. G. Sherburne Jr.; Assistant Director: Dorothy Schriver; Business Manager: Donald R. Harless; Things of Science: Ruby Yoshioka.